139 related articles for article (PubMed ID: 25455484)
1. The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Murakami M; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2014 Dec; 24(23):5460-5. PubMed ID: 25455484
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Murakami M; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2014 Nov; 24(22):5175-80. PubMed ID: 25442307
[TBL] [Abstract][Full Text] [Related]
3. 8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Mochida H; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2015 Apr; 25(7):1431-5. PubMed ID: 25754491
[TBL] [Abstract][Full Text] [Related]
4. Avanafil for erectile dysfunction.
Kyle JA; Brown DA; Hill JK
Ann Pharmacother; 2013 Oct; 47(10):1312-20. PubMed ID: 24259695
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK
BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738
[TBL] [Abstract][Full Text] [Related]
6. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Limin M; Johnsen N; Hellstrom WJ
Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
[TBL] [Abstract][Full Text] [Related]
7. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.
Yilmaz D; Bayatli N; Un O; Kadowitz PJ; Sikka SC; Gur S
Urology; 2014 Feb; 83(2):508.e7-12. PubMed ID: 24331245
[TBL] [Abstract][Full Text] [Related]
8. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
Kotera J; Mochida H; Inoue H; Noto T; Fujishige K; Sasaki T; Kobayashi T; Kojima K; Yee S; Yamada Y; Kikkawa K; Omori K
J Urol; 2012 Aug; 188(2):668-74. PubMed ID: 22704456
[TBL] [Abstract][Full Text] [Related]
9. Avanafil (Stendra)--another PDE5 inhibitor for erectile dysfunction.
Med Lett Drugs Ther; 2014 May; 56(1442):37-8. PubMed ID: 24818838
[No Abstract] [Full Text] [Related]
10. Avanafil - a further step to tailoring patient needs and expectations.
Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
[TBL] [Abstract][Full Text] [Related]
11. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs.
Mochida H; Yano K; Inoue H; Yee S; Noto T; Kikkawa K
J Urol; 2013 Aug; 190(2):799-806. PubMed ID: 23321580
[TBL] [Abstract][Full Text] [Related]
12. Avanafil for the treatment of erectile dysfunction.
Segal R; Burnett AL
Drugs Today (Barc); 2012 Jan; 48(1):7-15. PubMed ID: 22384456
[TBL] [Abstract][Full Text] [Related]
13. A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice.
Mirone V; Fusco F; Parazzini F; Zucchi A
Arch Ital Urol Androl; 2016 Jul; 88(2):128-32. PubMed ID: 27377089
[TBL] [Abstract][Full Text] [Related]
14. Avanafil for the treatment of erectile dysfunction.
Zurawin JL; Stewart CA; Anaissie JE; Yafi FA; Hellstrom WJ
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1163-70. PubMed ID: 27416913
[TBL] [Abstract][Full Text] [Related]
15. Avanafil for the treatment of erectile dysfunction. An updated review.
Egui-Rojo MA; Moncada-Iribarren I; Carballido-RodrÃguez J; MartÃnez-Salamanca JI
Arch Esp Urol; 2014 Dec; 67(10):839-47. PubMed ID: 25582903
[TBL] [Abstract][Full Text] [Related]
16. Avanafil for treatment of erectile dysfunction: review of its potential.
Burke RM; Evans JD
Vasc Health Risk Manag; 2012; 8():517-23. PubMed ID: 22973106
[TBL] [Abstract][Full Text] [Related]
17. Future prospects in the treatment of erectile dysfunction: focus on avanafil.
Alwaal A; Al-Mannie R; Carrier S
Drug Des Devel Ther; 2011; 5():435-43. PubMed ID: 22087063
[TBL] [Abstract][Full Text] [Related]
18. Avanafil: A comprehensive drug profile.
Al-Majed AA; AlKhairallah A; Attwa MW; Alkahtani HM; El-Azab AS; Abdel-Aziz AA; Alkhider A; Hassan SB; Bakheit AH
Profiles Drug Subst Excip Relat Methodol; 2024; 49():115-151. PubMed ID: 38423706
[TBL] [Abstract][Full Text] [Related]
19. Avanafil for male erectile dysfunction: a systematic review and meta-analysis.
Cui YS; Li N; Zong HT; Yan HL; Zhang Y
Asian J Androl; 2014; 16(3):472-7. PubMed ID: 24589460
[TBL] [Abstract][Full Text] [Related]
20. An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.
Belkoff LH; McCullough A; Goldstein I; Jones L; Bowden CH; DiDonato K; Trask B; Day WW
Int J Clin Pract; 2013 Apr; 67(4):333-41. PubMed ID: 23521325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
